Organon & Co. (OGN)
13.84
+0.05
(+0.36%)
USD |
NYSE |
Nov 06, 15:25
Organon Research and Development Expense (Annual) : 366.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 366.00M |
| December 31, 2024 | 469.00M |
| December 31, 2023 | 528.00M |
| December 31, 2022 | 471.00M |
| December 31, 2021 | 443.00M |
| Date | Value |
|---|---|
| December 31, 2020 | 210.00M |
| December 31, 2019 | 332.00M |
| December 31, 2018 | 365.00M |
| December 31, 2017 | 355.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viatris, Inc. | 952.50M |
| Pacira Biosciences, Inc. | 117.31M |
| Bristol Myers Squibb Co. | 9.492B |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |